Novartis Discloses Tumor Reports After Zolgensma Treatment

Company Novartis Event Type Safety disclosure Modality AAV9 gene therapy Asset Zolgensma (onasemnogene abeparvovec) Target SMN1 gene replacement Disease Area Spinal muscular atrophy Summary A November 5 Novartis statement disseminated by SMA patient organizations reports nine tumors worldwide in children previously treated with Zolgensma among…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *